CA2032138A1 - Cellules t anti-ergotypiques pour le traitement ou la prevention des maladies anto-immunes et leurs modes d'utilisation - Google Patents
Cellules t anti-ergotypiques pour le traitement ou la prevention des maladies anto-immunes et leurs modes d'utilisationInfo
- Publication number
- CA2032138A1 CA2032138A1 CA002032138A CA2032138A CA2032138A1 CA 2032138 A1 CA2032138 A1 CA 2032138A1 CA 002032138 A CA002032138 A CA 002032138A CA 2032138 A CA2032138 A CA 2032138A CA 2032138 A1 CA2032138 A1 CA 2032138A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- ergotypic
- activated
- eae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 64
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract 8
- 238000000034 method Methods 0.000 title claims description 5
- 230000002265 prevention Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 239000012634 fragment Substances 0.000 claims abstract description 8
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 6
- 238000001727 in vivo Methods 0.000 claims abstract description 3
- 230000008569 process Effects 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 abstract description 9
- 230000004913 activation Effects 0.000 abstract description 7
- 239000003550 marker Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 60
- 241000700159 Rattus Species 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 238000001994 activation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000518994 Conta Species 0.000 description 2
- 241001669573 Galeorhinus galeus Species 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 238000009171 T-cell vaccination Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- WLWIMKWZMGJRBS-UHFFFAOYSA-N primin Chemical compound CCCCCC1=CC(=O)C=C(OC)C1=O WLWIMKWZMGJRBS-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- PYKLUAIDKVVEOS-RAXLEYEMSA-N (e)-n-(cyanomethoxy)benzenecarboximidoyl cyanide Chemical compound N#CCO\N=C(\C#N)C1=CC=CC=C1 PYKLUAIDKVVEOS-RAXLEYEMSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 101150103244 ACT1 gene Proteins 0.000 description 1
- 101150023426 Ccin gene Proteins 0.000 description 1
- 241000022841 Concana Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 101100507451 Drosophila melanogaster sip3 gene Proteins 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 101150039033 Eci2 gene Proteins 0.000 description 1
- 244000228957 Ferula foetida Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- HCIHJOTZGZSMLV-UHFFFAOYSA-N Lutinine Natural products O=C1C(=Nc2ccccc2)C=C(Nc3ccccc3)c4ccccc14 HCIHJOTZGZSMLV-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100032932 Mus musculus Raly gene Proteins 0.000 description 1
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- 241000282312 Proteles Species 0.000 description 1
- 101100463797 Rattus norvegicus Pgrmc1 gene Proteins 0.000 description 1
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000004543 Vicia ervilia Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 101150061668 nodQ gene Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34648689A | 1989-05-02 | 1989-05-02 | |
| US07/346,486 | 1989-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2032138A1 true CA2032138A1 (fr) | 1990-11-03 |
Family
ID=23359614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002032138A Abandoned CA2032138A1 (fr) | 1989-05-02 | 1990-04-30 | Cellules t anti-ergotypiques pour le traitement ou la prevention des maladies anto-immunes et leurs modes d'utilisation |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0427850A4 (fr) |
| JP (1) | JPH04500689A (fr) |
| CA (1) | CA2032138A1 (fr) |
| IL (1) | IL94270A0 (fr) |
| WO (1) | WO1990014068A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552300A (en) * | 1994-01-13 | 1996-09-03 | T Cell Sciences, Inc. | T cell antigen receptor V region proteins and methods of preparation thereof |
-
1990
- 1990-04-30 JP JP2510446A patent/JPH04500689A/ja active Pending
- 1990-04-30 WO PCT/US1990/002407 patent/WO1990014068A2/fr not_active Application Discontinuation
- 1990-04-30 EP EP19900911056 patent/EP0427850A4/en not_active Withdrawn
- 1990-04-30 CA CA002032138A patent/CA2032138A1/fr not_active Abandoned
- 1990-05-02 IL IL94270A patent/IL94270A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0427850A4 (en) | 1992-01-15 |
| EP0427850A1 (fr) | 1991-05-22 |
| IL94270A0 (en) | 1991-03-10 |
| WO1990014068A3 (fr) | 1991-02-07 |
| JPH04500689A (ja) | 1992-02-06 |
| WO1990014068A2 (fr) | 1990-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200360438A1 (en) | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination | |
| Mochizuki et al. | Immunological homeostasis of the eye | |
| US5962320A (en) | Engineered antigen presenting cells and methods for their use | |
| Cremel et al. | Red blood cells as innovative antigen carrier to induce specific immune tolerance | |
| BG106028A (bg) | Имунотерапия на рак чрез експресия на скъсен туморен или тумор-асоцииран антиген | |
| US10179164B2 (en) | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions | |
| EP2029165B1 (fr) | Vaccin basé sur un lymphocyte b chargé avec le ligand du lymphocyte t nk et antigène | |
| JP2002515734A (ja) | 遺伝子改変された樹状細胞により媒介される免疫刺激 | |
| Xu et al. | A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP | |
| JP2002501377A (ja) | 樹状細胞ハイブリッド | |
| JP2000512127A (ja) | ヒトｈｌａ拘束性腫瘍抗原に特異的なｔ細胞受容体をコードする組み換え体 | |
| BRPI0116013B1 (pt) | Composição farmacêutica para potenciar a imunogenicidade de antígenos pouco imunogênicos, e, uso da composição farmacêutica | |
| Willimsky et al. | Interleukin-7/B7. 1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors | |
| BR112020016876A2 (pt) | Células apresentadoras de antígeno universal e usos das mesmas | |
| CA2032138A1 (fr) | Cellules t anti-ergotypiques pour le traitement ou la prevention des maladies anto-immunes et leurs modes d'utilisation | |
| Linington et al. | Induction of experimental allergic neuritis in the BN rat: P2 protein-specific T cells overcome resistance to actively induced disease. | |
| Garrido et al. | Immunogenicity of H‐2 positive and H‐2 negative clones of a mouse tumour, GR9 | |
| EP0261648B1 (fr) | Protéines de membrane cellulaire, compositions les contenant et procédé pour les préparer | |
| US20100028380A1 (en) | B cell-based vaccine loaded with the ligand of natural killer t cell and antigen | |
| JP7416629B2 (ja) | 免疫応答を増強するための物質および方法 | |
| CN102154302A (zh) | 一种可溶性人重组mica蛋白的制备方法 | |
| Geiger | The T cell response to SV40 large-T expressed outside the thymus | |
| Suzan et al. | The 5936 Ig‐Idiotype (s): Genetic Linkage to Ig‐CH Loci, T‐Cell Dependence of Synthesis and Possible Specificities | |
| Primus et al. | Mice transgenic for the CEA gene as a model for cancer immunotherapy and antibody targeting studies | |
| JP2011102320A (ja) | ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19941101 |